C3N-00199
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 65.7357974
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.230
- GLYCOLYSIS+0.120
- UV_RESPONSE_DN+0.100
- PROTEIN_SECRETION+0.090
- SPERMATOGENESIS+0.090
- APICAL_SURFACE+0.080
- NOTCH_SIGNALING+0.080
- BILE_ACID_METABOLISM+0.060
- HEME_METABOLISM+0.060
- WNT_BETA_CATENIN_SIGNALING+0.060
Top 10 suppressed
- MYC_TARGETS_V2-0.500
- ALLOGRAFT_REJECTION-0.480
- INFLAMMATORY_RESPONSE-0.430
- MYC_TARGETS_V1-0.430
- IL6_JAK_STAT3_SIGNALING-0.410
- INTERFERON_GAMMA_RESPONSE-0.410
- INTERFERON_ALPHA_RESPONSE-0.390
- TNFA_SIGNALING_VIA_NFKB-0.380
- UNFOLDED_PROTEIN_RESPONSE-0.370
- IL2_STAT5_SIGNALING-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A09V-01A-11R-A034-07 | — | B | 0.827 |
| 2 | MNG13 | — | — | 0.825 |
| 3 | TCGA-J2-A4AD-01A-11R-A24H-07 | — | cohortA1 | 0.821 |
| 4 | TCGA-HD-7754-01A-11R-2081-07 | — | — | 0.819 |
| 5 | SRR8518441 | — | D | 0.813 |
| 6 | TCGA-BL-A0C8-01B-04R-A277-07 | — | — | 0.811 |
| 7 | TCGA-A8-A091-01A-11R-A00Z-07 | — | B | 0.809 |
| 8 | MNG214 | — | — | 0.805 |
| 9 | TCGA-A7-A4SB-01A-21R-A266-07 | — | B | 0.803 |
| 10 | BSR_16_0051_A2_S82 | — | A | 0.796 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.090 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.080 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.060 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.020 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.010 | Inavolisib | — uncovered |